FL-NEURON
9.4.2024 14:01:32 CEST | Business Wire | Press release
Neuron, a QoE management platform for things that move, announced today that it’s making its network APIs available to maritime solution providers and app developers to enable application-driven quality of experience (QoE) on demand. With Neuron’s network APIs, cruise, shipping, energy and more can reimagine connectivity and QoE for critical onboard services such as medical, disaster response, remote monitoring and management and more, resulting in higher standards of safety and well-being for passengers and crew.
As part of today’s announcement, Neuron, VIKAND, a global leader in maritime healthcare, and FrontM, creator of a low code software platform for maritime, have unveiled a partnership to explore a variety of ways to transform onboard medical services across the maritime industry.
Bandwidth Orchestration in Maritime is Highly Manual and Inefficient
During emergency situations at sea, the apps and services supporting response efforts need exponentially more bandwidth, with elevated QoE, to accelerate response times, communication and decision-making. Consider an already busy network with passengers, crew and corporate teams using the majority of available data capacity, and then add to the mix a medical team managing an emergency on the ship – they might need more than 100 Mbps of symmetrical bandwidth on demand to transfer large files, conduct an HD video conference with remote specialists, perform telediagnosis and more.
Today, it’s not possible to dynamically orchestrate bandwidth across multiple providers and update QoS and network configurations for short periods of time, while also ensuring a high-quality end-user experience – without disrupting all other activity on the ship. Instead, cruise teams have to manually configure and provision capacity to manage this type of request, and prioritize and allocate the bandwidth to the application accordingly. This process is clunky, expensive and can often take days, leaving onboard solution teams to resort to workarounds that are less efficient.
Neuron Network APIs Enable Multi-Provider, AI-Powered Connectivity Orchestration
With Neuron’s network APIs, maritime solution providers and app developers can connect their apps directly to Neuron’s AI-powered network management solution, Neuron Grid, to programmatically request QoE on demand. When an app triggers a request, Neuron will use AI and machine learning to orchestrate network changes and deliver the capacity the app needs, in real-time, with the most optimal QoE – all the onboard team needs to do is press a button in an app. Unlike other network management solutions, Neuron can seamlessly blend any combination of connectivity – whether single- or multi-provider, -orbit or -network – in one, vendor-neutral environment.
“Telecom network APIs are incredibly powerful, but they’ve always been focused on cellular, limiting their value for maritime companies that rely on LTE, satellite and Wi-Fi,” said Benny Retnamony, founder and CEO, Neuron. “Because Neuron enables multi-provider access with AI-powered network management, we are uniquely positioned to facilitate application-driven QoE on demand for the maritime industry. We look forward to collaborating with a range of maritime solution providers to unlock the next generation of apps and services at sea.”
Neuron, VIKAND and FrontM Partner to Transform Onboard Medical Services
Neuron, VIKAND and FrontM are collaborating to explore a variety of ways to use Neuron’s QoE management platform to rethink both emergency and non-emergency medical services for maritime. With Neuron’s network APIs, VIKAND can ensure continuity of care, especially in the event of an emergency when reliable, high-quality connectivity is critical. This will make it possible for doctors to use modern digital imaging equipment for high-resolution X-rays and ultrasounds, or more advanced medical equipment, like smart stethoscopes, right from the ship.
- “On-demand, agile and elastic connectivity is needed to enable advanced healthcare technologies and solutions at sea,” added Benny Retnamony, founder and CEO of Neuron. “Through our partnership with VIKAND and FrontM, we are committed to demonstrating how application-driven QoE on demand orchestrated through the Neuron platform can clear the way for VIKAND to accelerate access to critical onboard medical services.”
- “Technology and connectivity are critical to any vessels at sea,” says Ronald Spithout, Managing Director of OneHealth by VIKAND. “VIKAND together with FrontM are always striving to deploy state of the art modern technology to improve healthcare possibilities at sea. In this context, the integration with Neuron's quality of experience management platform opens the possibility to automatically link available capacity that best matches the specific application requirement of that very moment, which could make all the difference when talking healthcare and/or medical emergencies. VIKAND is delighted to be partnering with Neuron to deploy this technology to the benefit of improving welfare at sea, where it adds value to our operations, preserves crew value and benefits the maritime industry as a whole.”
- Guillermo Acilu, CTO, FrontM adds, “We are excited to harness enhanced connectivity by combining Neuron’s network management API and FrontM’s low-code frameworks for Vikand’s healthcare solution. This is groundbreaking for not only Vikand’s doctors and the crew to access advanced solutions with dynamically elevated connectivity but also to bring efficiency and assurance to the customer at the same time. This partnership with Neuron opens up significant opportunities to maximise the customer experience for a vast array of applications in our app marketplace.”
Click here to view a short demo video by Neuron, VIKAND and FrontM.
Unlocking the Next Generation of Apps and Services at Sea
Application-driven QoE on demand for critical onboard services is just the beginning. In the future, maritime solution providers can also use Neuron’s network APIs to unlock differentiated and personalized passenger experiences. For example, tailoring IPTV content and quality for special events, like Sunday Night Football; dynamic content caching prepositioning for high-definition VoD; or throwing hyper-connected live events and festivals in the middle of the ocean.
Neuron is committed to working with additional partners to explore new ways to use its network APIs for a diverse range of use cases.
About Neuron
Neuron is the first AI-powered QoE management platform for things that move. It uses AI and machine learning to seamlessly blend any combination of connectivity, regardless of provider, orbit or network, in one, vendor-neutral environment, enabling comprehensive analytics and dynamic network orchestration that optimizes for the best possible quality of experience (QoE) – even in the most remote and hard-to-reach places.
Today, Neuron works with world-leading, Fortune 500 companies in aviation, cruise, shipping and more. To learn more, visit: www.getneuron.com and follow us on LinkedIn.
About VIKAND
VIKAND is a leading expert in global medical services and risk mitigation solutions for the maritime industry, operating a global network of 1,500 maritime medical professionals, established across 44 countries, supported by 4 main locations. VIKAND’s caring and committed teams manage more than 4,100 daily maritime medical encounters.
With OneHealth, VIKAND offers a preventive maintenance approach to optimizing the physical and mental health of seafarers. A ship at sea is a standalone ecosystem where people live and work interdependently. OneHealth takes a diversified and inclusive approach to protecting the health and wellness of all onboard.
VIKAND all-inclusive approach unifies preparedness, prevention, detection, response, and management across a range of healthcare concerns, from communicable diseases to chronic illnesses, mental health concerns and more. www.vikand.com
About FrontM
FrontM is a UK Headquartered, collaboration software company offering a comprehensive superapp platform for the maritime industry. By connecting service providers, solution providers, ship operators and their crews, FrontM facilitates improved communications, collaboration, crew welfare and operational efficiency at sea.
Delivering a unique suite of marketplace apps for companies to prioritise crew connectivity and operate the ship as an extension of the shore ranging from crew healthcare enabling medical specialists to deliver comprehensive care, to crew training and skills development with social and just-in-time learning tools, crew entertainment with the industry’s first live IP-TV, together with crew social internet, video conferencing and virtual events.
With a focus on digitalisation and a one-stop solution for integrating services, FrontM is dedicated to overcoming the challenges of app fatigue and advancing the maritime industry's digital transformation. www.frontm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409591486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
